EVFM on OTC

Evofem Biosciences, Inc.

American pharmaceutical preparations company based in San Diego. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with SCYNEXIS INC, CASI Pharmaceuticals, Inc. or Sol-Gel Technologies Ltd., or pick any stock.

  • TickerEVFM on OTC2
  • IndustryPharmaceutical Preparations2
  • HeadquartersSan Diego, United States2
  • Incorporated inDE3
  • Business address12400 High Bluff Drive, Suite 600, San Diego, Ca 921303
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493007VAGG43TIEJW572
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 40557782

See how the biggest companies compare on our leaderboards

No. 539. August 2025. Data table for Figure 1, sourced from National Survey of Family Growth (NSFG) 2022–2023.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

16.7%Operating margin5
1.9%Net margin5
4.2%Revenue growth, 20255
-$2.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue23¢$4.6M
  • Other costs63¢$12.8M
  • Interest12¢$2.4M
  • Income tax0¢$2.0K
  • Profit2¢$391.0K

Out of $20.2M in revenue.5

Financial statements

Revenue6789105$20.2M in 2025
0$10.0M$20.0M$30.0M2019: $0$020192020: $446.0K$446.0K20202021: $8.2M$8.2M2021+1748%2022: $16.8M$16.8M2022+104%2023: $18.2M$18.2M2023+8%2024: $19.4M$19.4M2024+6%2025: $20.2M$20.2M2025+4%
Operating income6789105$3.4M in 2025
-$200.0M-$150.0M-$100.0M-$50.0M0$50.0M2019: -$52.7M-$52.7M20192020: -$103.6M-$103.6M2020+96%2021: -$166.8M-$166.8M2021+61%2022: -$84.1M-$84.1M2022−50%2023: -$17.8M-$17.8M2023−79%2024: -$7.7M-$7.7M2024−57%2025: $3.4M$3.4M2025
Net income6789105$391.0K in 2025
-$300.0M-$200.0M-$100.0M0$100.0M2019: -$80.0M-$80.0M20192020: -$142.3M-$142.3M2020+78%2021: -$205.2M-$205.2M2021+44%2022: -$76.7M-$76.7M2022−63%2023: $53.0M$53.0M20232024: -$8.9M-$8.9M20242025: $391.0K$391.0K2025
Fiscal year2019202020212022202320242025
Revenue$06$446.0K7$8.2M8$16.8M9$18.2M10$19.4M5$20.2M5
Cost of revenue$06$468.0K7$4.1M8$4.4M9$6.5M10$3.8M5$4.6M5
Research and development$22.2M6$17.1M7$33.1M8$25.0M9$2.9M10$1.8M10
Operating expenses$175.0M8$101.0M9$36.1M10$27.0M5$16.8M5
Operating income-$52.7M6-$103.6M7-$166.8M8-$84.1M9-$17.8M10-$7.7M5$3.4M5
Interest$06$2.1M7$2.7M8$2.2M9$2.3M10$2.2M5$2.4M5
Income before tax-$205.2M8-$76.7M9$53.0M10-$8.9M5$393.0K5
Income tax$4.0K6$4.0K7$17.0K8$44.0K9$17.0K10$2.0K5
Net income-$80.0M6-$142.3M7-$205.2M8-$76.7M9$53.0M10-$8.9M5$391.0K5
Earnings per share-$2.127-$23.638-$167.429$10.3610-$0.115$0.005
Earnings per share (diluted)-$2.127-$23.638-$167.429$0.0510-$0.115$0.005
Shares (weighted, basic)8.7M shares8466.0K shares94.8M shares1080.0M shares5123.7M shares5
Shares (weighted, diluted)8.7M shares8466.0K shares9984.0M shares1080.0M shares56.4B shares5

Compare Evofem Biosciences, Inc. with another company

Leadership

Who has led Evofem Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. George W. Mahaffey2014–2015
  2. Saundra L. Pelletier2018–2023

President

  1. George W. Mahaffey2014–2015

Chief financial officer

  1. Susan A. Knudson2014–2017
201520202025
Board members and other officers (24)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerIvy Zhang named Oct 11, 2023 to Jul 2, 202538
  • Executive OfficerJustin File named Feb 3, 2023 to Mar 6, 202339
  • DirectorTony O'Brian named Feb 3, 2023 to Mar 6, 202339

Former names

  • Neothetics, Inc.Sep 12, 2014 to Jan 5, 20183

Timeline

  1. Jan 18, 2018New chief executive Saundra L. Pelletier becomes CEO13
  2. Nov 19, 2014New chief executive George W. Mahaffey becomes CEO14
  3. Feb 1, 2007Founded Evofem Biosciences, Inc. is founded2

Filings

237 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 131 major events, 22 insider forms, 5 large holders, 7 private raises, 51 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Sep 23, 20268-K EDGAR
  3. Aug 14, 202610-Q EDGAR
  4. Jul 20, 20268-K EDGAR
  5. Jul 14, 20268-K EDGAR
  6. May 18, 20268-K EDGAR
  7. May 15, 202610-Q EDGAR
  8. Apr 30, 20268-K EDGAR
  9. Apr 16, 20268-K EDGAR
  10. Mar 19, 20268-K EDGAR
  11. Mar 11, 20268-K EDGAR
  12. Mar 11, 202610-K EDGAR
  13. Jan 12, 20268-K EDGAR
  14. Nov 26, 20258-K EDGAR
  15. Nov 13, 20258-K EDGAR
  16. Nov 13, 202510-Q EDGAR
  17. Oct 29, 2025DEF 14A EDGAR
  18. Oct 20, 2025PRE 14A EDGAR
  19. Oct 20, 20258-K EDGAR
  20. Oct 17, 20258-K EDGAR

The 237 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 4 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 12, 2024Zhang YanCFOSale104$0.04$4Form 4
Dec 21, 2023Kamdar Kim P.DirectorSale10$0.62$6Form 4
May 27, 2022PELLETIER SAUNDRA LChief Executive OfficerBuy141,000$0.35$49.4KForm 4
Dec 20, 2021Fitzpatrick Alexander AGeneral Counsel and SecretaryBuy25,000$0.39$9.8KForm 4
Dec 20, 2021File Justin J.Chief Financial OfficerBuy40,594$0.37$15.0KForm 4
Dec 20, 2021PELLETIER SAUNDRA LChief Executive OfficerBuy135,000$0.38$51.3KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • CVI Investments, Inc.SC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202440
  • Todd Stewart CoxSC 13G/A, 2 filings Jul 19, 2022 to Aug 10, 202241

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jun 26, 2025Raised $925,000 in a private offering of equity Form D: 1 investor so far Form D
  2. Apr 8, 2025Raised $750,000 in a private offering of equity Form D: $1.5 million offered in all Form D
  3. Aug 9, 2024Raised $500,000 in a private offering of equity Form D: 1 investor so far Form D
  4. Jul 12, 2024Raised $500,000 in a private offering of equity Form D: 1 investor so far Form D
  5. Sep 27, 2023Raised $2.9 million in a private offering of debt Form D: 14 investors so far Form D
  6. Feb 17, 2023Raised $1.4 million in a private offering of debt Form D: 4 investors so far Form D
  7. Dec 20, 2022Raised $2.3 million in a private offering of securities Form D: 8 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41